<mets:mets OBJID="eprint_4346" LABEL="Eprints Item" xsi:schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mets="http://www.loc.gov/METS/" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mets:metsHdr CREATEDATE="2026-07-07T07:51:31Z"><mets:agent ROLE="CUSTODIAN" TYPE="ORGANIZATION"><mets:name>Repositori BKPK</mets:name></mets:agent></mets:metsHdr><mets:dmdSec ID="DMD_eprint_4346_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:titleInfo><mods:title>Laporan Riset IPTEKKES 2019 Profil Imunoekspresi C-X-C Chemokine Receptor Type 4 (CXCR4), Mammalian Target of Rapamycin (mTOR), Nuclear Factor kB (NF-kB), dan Programmed Death Ligand (PD-L1) pada Pasien Limfoma Non-Hodgkin tipe Diffuse Large B-cell di RSUP Dr. Hasan Sadikin</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Birgitta M.</mods:namePart><mods:namePart type="family">Dewayani</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Herry</mods:namePart><mods:namePart type="family">Yulianti</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Fety</mods:namePart><mods:namePart type="family">Riani</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:name type="personal"><mods:namePart type="given">Bhayu Chandra</mods:namePart><mods:namePart type="family">Purnomo</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Limfoma non-Hodgkin tipe diffuse large B cell (LNH tipe DLBC) adalah LNH yang paling sering terjadi di seluruh dunia. Pengobatan rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristine), and prednisone (R-CHOP) saat ini merupakan terapi standar untuk LNH tipe DLBC. Walaupun demikian terjadi refractory pada 10% kasus pada penderita LNH tipe DLBC walaupun telah mendapat terapi R-CHOP sehingga memiliki prognosis yang lebih buruk. Untuk meningkatkan angka kesembuhan dan harapan hidup pasien LNH tipe DLBC saat ini sedang dikembangkan terapi target, di antaranya inhibitor&#13;
terhadap C-X-C chemokine receptor type 4 (CXCR4), mammalian target of rapamycin (mTOR), nuclear factor-kB (NF-kB), dan imunoterapi anti programmed death ligand 1 (PD-L1). Penelitian ini ditujukan untuk melihat gambaran ekspresi dan relevansi klinis keempat biomarker tersebut pada populasi pasien LNH tipe DLBC di Indonesia.&#13;
Penelitian ini melibatkan 60 kasus baru yang didiagnosis sebagai LNH tipe DLBC di RSUP Dr. hasan Sadikin Bandung selama periode Januari 2015 hingga Agustus 2019. Pemeriksaan imunohistokimia (IHK) CXCR4, mTOR, Nf-kB, dan PD-L1 dilakukan pada blok parafin massa tumor pasien. Data klinis diperoleh dari berkas rekam medis.&#13;
Imunoekspresi CXCR4 tinggi sebanyak 30 kasus (50,0%), imunoekspresi NF-kB tinggi hanya sebanyak 1 kasus (1,7%), sedangkan imunoekspresi PD-L1 tinggi sebanyak 16 kasus (26,7%). Terdapat hubungan yang signifikan antara imunoekspresi CXCR4 dengan keterlibatan lebih dari satu organ ekstranodal (p=0,007) dan gejala B (p = 0,037).&#13;
Imunoekspresi CXCR4, mTOR, NF-kB, dan PD-L1 tinggi terdeteksi pada sebagian kasus LNH tipe DLBC pada populasi pasien LNH tipe  DLBC di RSUP Dr. Hasan Sadikin Bandung. Imunoekspresi CXCR4, mTOR, NF-kB dan PD-L1  secara umum tidak berhubungan secara signifikan dengan berbagai karakteristik klinis pada pasien LNH tipe DLBC di RSUP Dr. Hasan Sadikin Bandung, kecuali imunoekspresi CXCR4 yang berhubungan secara signifikan dengan keterlibatan organ ekstranodal &gt;1 dan gejala B</mods:abstract><mods:classification authority="lcc">WH 120-540 Hematologic Diseases. Immunologic Factors. Blood Banks</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8601">2019</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Badan Penelitian dan Pengembangan Kesehatan dan FK Universitas Padjadjaran</mods:publisher></mods:originInfo><mods:genre>Monograph</mods:genre></mets:xmlData></mets:mdWrap></mets:dmdSec><mets:amdSec ID="TMD_eprint_4346"><mets:rightsMD ID="rights_eprint_4346_mods"><mets:mdWrap MDTYPE="MODS"><mets:xmlData><mods:useAndReproduction>
<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by its own author:</strong>
In self-archiving this collection of files and associated bibliographic
metadata, I grant Repositori BKPK the right to store
them and to make them permanently available publicly for free on-line.
I declare that this material is my own intellectual property and I
understand that Repositori BKPK does not assume any
responsibility if there is any breach of copyright in distributing these
files or metadata. (All authors are urged to prominently assert their
copyright on the title page of their work.)</p>

<p xmlns="http://www.w3.org/1999/xhtml"><strong>For work being deposited by someone other than its
author:</strong> I hereby declare that the collection of files and
associated bibliographic metadata that I am archiving at
Repositori BKPK is in the public domain. If this is
not the case, I accept full responsibility for any breach of copyright
that distributing these files or metadata may entail.</p>

<p xmlns="http://www.w3.org/1999/xhtml">Clicking on the <em>Deposit Item Now</em> button indicates your agreement to these
terms.</p>
    </mods:useAndReproduction></mets:xmlData></mets:mdWrap></mets:rightsMD></mets:amdSec><mets:fileSec><mets:fileGrp USE="reference"><mets:file ID="eprint_4346_13013_1" SIZE="8812373" OWNERID="http://www.badankebijakan.kemkes.go.id/repositori/id/eprint/4346/1/Laporan%20Riset%20IPTEKKES%202019%20Profil%20Imunoekspresi%20C-X-C%20Chemokine%20Receptor%20Type%204%20%28CXCR4%29%2C%20Mammalian%20Target%20of%20rapamycin%20%28mTor%29%2C%20Nuclear%20Factor%20kB%20%28NF-kB%29%2C%20dan%20programmed%20death%20Ligand%20%28PD-L1%29%20pada%20Pasien%20Limfoma%20Non-Hodgkin.pdf" MIMETYPE="application/pdf"><mets:FLocat LOCTYPE="URL" xlink:type="simple" xlink:href="http://www.badankebijakan.kemkes.go.id/repositori/id/eprint/4346/1/Laporan%20Riset%20IPTEKKES%202019%20Profil%20Imunoekspresi%20C-X-C%20Chemokine%20Receptor%20Type%204%20%28CXCR4%29%2C%20Mammalian%20Target%20of%20rapamycin%20%28mTor%29%2C%20Nuclear%20Factor%20kB%20%28NF-kB%29%2C%20dan%20programmed%20death%20Ligand%20%28PD-L1%29%20pada%20Pasien%20Limfoma%20Non-Hodgkin.pdf"></mets:FLocat></mets:file></mets:fileGrp></mets:fileSec><mets:structMap><mets:div DMDID="DMD_eprint_4346_mods" ADMID="TMD_eprint_4346"><mets:fptr FILEID="eprint_4346_document_13013_1"></mets:fptr></mets:div></mets:structMap></mets:mets>